WO2010085100A2 - 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템 - Google Patents

신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템 Download PDF

Info

Publication number
WO2010085100A2
WO2010085100A2 PCT/KR2010/000395 KR2010000395W WO2010085100A2 WO 2010085100 A2 WO2010085100 A2 WO 2010085100A2 KR 2010000395 W KR2010000395 W KR 2010000395W WO 2010085100 A2 WO2010085100 A2 WO 2010085100A2
Authority
WO
WIPO (PCT)
Prior art keywords
transmembrane domain
cellular transmembrane
transduction system
same
system containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2010/000395
Other languages
English (en)
French (fr)
Other versions
WO2010085100A3 (ko
Inventor
김재일
박진석
김현진
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gwangju Institute of Science and Technology
Anygen Co Ltd
Original Assignee
Gwangju Institute of Science and Technology
Anygen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gwangju Institute of Science and Technology, Anygen Co Ltd filed Critical Gwangju Institute of Science and Technology
Publication of WO2010085100A2 publication Critical patent/WO2010085100A2/ko
Publication of WO2010085100A3 publication Critical patent/WO2010085100A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)

Abstract

본 발명은 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템에 관한 것이다. 본 발명의 세포막 투과 도메인은 기존의 바이러스로부터 유래된 펩타이드 또는 서열 특이적으로 설계된 펩타이드들과 비교할 때, 유전적인 면역 문제 또는 세포 독성에 있어서 매우 우수한 효과를 나타낼 수 있기 때문에, 부작용의 우려 없이 임상적으로 인체에 적용할 수 있으며, 여러 질병에 관한 진단 및 신약 개발에도 활용할 수 있다.
PCT/KR2010/000395 2009-01-21 2010-01-21 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템 Ceased WO2010085100A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0004863 2009-01-21
KR1020090004863A KR101169030B1 (ko) 2009-01-21 2009-01-21 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템

Publications (2)

Publication Number Publication Date
WO2010085100A2 true WO2010085100A2 (ko) 2010-07-29
WO2010085100A3 WO2010085100A3 (ko) 2010-11-11

Family

ID=42356331

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/000395 Ceased WO2010085100A2 (ko) 2009-01-21 2010-01-21 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템

Country Status (2)

Country Link
KR (1) KR101169030B1 (ko)
WO (1) WO2010085100A2 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104822698A (zh) * 2012-07-11 2015-08-05 杰姆维克斯&凯尔有限公司 细胞穿透肽以及包含该肽的缀合物和组合物

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2621337T3 (es) * 2011-11-23 2017-07-03 Procell Therapeutics Inc. Desarrollo de nuevo dominio de transducción macromolecular con mejor permeabilidad celular y método de uso del mismo
ES2691070T3 (es) 2012-05-11 2018-11-23 Kael-Gemvax Co.,Ltd Péptidos antiinflamatorios y composición que comprende los mismos
WO2013169060A1 (ko) 2012-05-11 2013-11-14 주식회사 카엘젬백스 패혈증 예방 또는 치료용 조성물
TWI678374B (zh) * 2012-09-19 2019-12-01 韓商傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物(三)
US9631184B2 (en) 2012-09-19 2017-04-25 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
TWI616531B (zh) 2012-09-19 2018-03-01 傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物（二）
KR101636542B1 (ko) * 2012-10-09 2016-07-07 한양대학교 산학협력단 인간 ｎｌｂｐ 유래의 ｎｐ12 폴리펩티드 또는 ｎｐ21 폴리펩티드를 포함하는 세포 투과 펩티드 및 이를 이용한 카고 전달 시스템
KR101475744B1 (ko) * 2013-03-08 2014-12-24 서울대학교산학협력단 세포 투과 펩타이드
KR102258864B1 (ko) 2013-04-19 2021-06-01 주식회사 젬백스앤카엘 허혈성 손상 치료 및 예방용 조성물
TWI539960B (zh) 2013-06-21 2016-07-01 凱爾傑姆維克斯有限公司 激素分泌調節劑、包括其的組成物以及其用途
US9757473B2 (en) 2013-07-12 2017-09-12 Gemvax & Kael Co., Ltd. Cell-penetrating peptide and conjugate comprising same
CA2926183C (en) 2013-10-23 2018-07-03 Gemvax & Kael Co., Ltd. Composition for treating and preventing benign prostatic hyperplasia
EP3072519B1 (en) 2013-11-22 2020-08-19 Gemvax & Kael Co., Ltd. Peptide having angiogenesis inhibitory activity and composition containing same
ES2809251T3 (es) 2013-12-17 2021-03-03 Gemvax & Kael Co Ltd Composición para tratar cáncer de próstata
KR102166549B1 (ko) * 2014-01-10 2020-10-16 주식회사 젬백스앤카엘 혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트
JP6420459B2 (ja) 2014-04-11 2018-11-07 ジェムバックス アンド カエル カンパニー，リミティド 線維症抑制活性を有するペプチド及びこれを含む組成物
US10662223B2 (en) 2014-04-30 2020-05-26 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
WO2016006744A1 (ko) * 2014-07-11 2016-01-14 주식회사 프로셀테라퓨틱스 세포 내 분자 전송 펩티드를 이용한 경피 전달용 펩티드-sirna 복합체 및 이의 용도
KR101695792B1 (ko) * 2014-09-04 2017-01-12 디오셀 주식회사 신규 세포막 투과 펩티드 및 생리활성 물질 전달체로서의 그의 용도
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
KR102636129B1 (ko) 2015-02-27 2024-02-14 주식회사 젬백스앤카엘 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물
WO2016190660A1 (ko) 2015-05-26 2016-12-01 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
EP3318265B1 (en) 2015-07-02 2021-08-18 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
EP4272829A3 (en) 2016-04-07 2024-01-17 Gemvax & Kael Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
CA3179430A1 (en) 2020-05-19 2021-11-25 Jaeil Kim Novel nucleolin-binding peptide and use thereof
WO2022245136A1 (ko) 2021-05-18 2022-11-24 애니젠 주식회사 뉴클레오린-결합 펩타이드를 포함하는 항바이러스 조성물
WO2023090935A1 (ko) * 2021-11-18 2023-05-25 애니젠 주식회사 뉴클레오린에 특이적으로 결합하는 agm 펩타이드를 제조하는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097671A1 (en) * 2002-03-29 2003-11-27 Creagene Inc. Cytoplasmic transduction peptides and uses thereof
KR100859972B1 (ko) * 2006-02-20 2008-09-25 이화여자대학교 산학협력단 막투과 단백질 도메인 펩타이드

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104822698A (zh) * 2012-07-11 2015-08-05 杰姆维克斯&凯尔有限公司 细胞穿透肽以及包含该肽的缀合物和组合物
CN104822698B (zh) * 2012-07-11 2018-08-10 珍白斯凯尔有限公司 细胞穿透肽以及包含该肽的缀合物和组合物

Also Published As

Publication number Publication date
WO2010085100A3 (ko) 2010-11-11
KR20100085527A (ko) 2010-07-29
KR101169030B1 (ko) 2012-07-26

Similar Documents

Publication Publication Date Title
WO2010085100A2 (ko) 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템
WO2012038061A3 (en) Nanocapsules containing microemulsions
EP3050876A3 (en) Kinase modulators
WO2010069532A8 (en) Antibodies against human angiopoietin 2
WO2009108730A3 (en) Forms of rifaximin and uses thereof
WO2009060097A3 (de) Hygiene- oder pflegeartikel, aufweisend einen anteil an hydroaktiven polymeren, und eine zubereitung aufweisend bakteriophagen oder mindestens einen bestandteil derselben
WO2011157741A3 (en) Human antibody drug conjugates against tissue factor
BRPI0918139A2 (pt) composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos e uso
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
WO2009024677A3 (fr) Utilisation d ' acide hyaluronique pour la preparation de compositions destinees a l' amelioration de la fonction de protection de la peau, de l' oeil et des muqueuses
AP2957A (en) New antibodies specific of the Beta-amyloid peptides and their uses as diagnostic agents or drugs
IL219876A (en) Antibodies against human 1h-7b or its fragment, preparations containing them and their use in the preparation of drugs
WO2008141308A3 (en) Gene expression and pain
CA2821268C (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
WO2011106376A3 (en) Use of microvesicles in the treatment of medical conditions
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
EP2841107A4 (en) CYTOTOXIC ACTIVITIES DISPOSED OF HIV RELEASING MOLECULES (CDM-HS), CYTOTOXIC EFFECT AGAINST HUMAN IMMUNE WEAKAGE VIRUS AND METHOD OF USE
WO2009071690A3 (de) 5,6-disubstituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
WO2010046061A3 (de) Kosmetische und/oder pharmazeutische zubereitungen
ZA201009097B (en) C-ring-substituted pregn-4-ene-21,17-carbolactone,and pharmaceutical preparations comprising the latter
CO6290689A2 (es) Derivados de 1,2,3,4-tetrahidropirrolo[1,2]pirazina-6-carboxamidas y de 2,3,4,5-tetrahidropirrol[1,2][1,4]-diazepina -7-carboxamidas su preparacion y su aplicacion en terapeutica
WO2008113770A3 (en) Anti-androgen peptides and uses thereof in cancer therapy
WO2010052243A3 (en) Neurotensin-derived branched peptides and uses thereof
WO2008120263A3 (en) Prokineticins receptors antagonists, derivatives and uses thereof
WO2011114071A3 (fr) Cyclopeptide synthetique, procede de preparation et utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10733653

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10733653

Country of ref document: EP

Kind code of ref document: A2